Kirk O - Search Results

1

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study.

Hatleberg CI, Ryom L, Kamara D, De Wit S, Law M, Phillips A, Reiss P, D'Arminio Monforte A, Mocroft A, Pradier C, Kirk O, Kovari H, Bonnet F, El-Sadr W, Lundgren JD, Sabin C; D:A:D Study Group. Hatleberg CI, et al. Among authors: kirk o. EClinicalMedicine. 2019 Aug 11;13:91-100. doi: 10.1016/j.eclinm.2019.07.008. eCollection 2019 Aug. EClinicalMedicine. 2019. PMID: 31517266 Free PMC article.

2

A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.

Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O, Phillips AN; EuroSIDA Study Group. Lundgren JD, et al. Among authors: kirk o. J Infect Dis. 2002 Jan 15;185(2):178-87. doi: 10.1086/338267. Epub 2002 Jan 3. J Infect Dis. 2002. PMID: 11807691 Free article.

3

Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.

Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD. Miller V, et al. Among authors: kirk o. J Infect Dis. 2002 Jul 15;186(2):189-97. doi: 10.1086/341466. Epub 2002 Jul 3. J Infect Dis. 2002. PMID: 12134254 Free article. Clinical Trial.

4

Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.

Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H; European HIV Cohorts. Kirk O, et al. Ann Intern Med. 2002 Aug 20;137(4):239-50. doi: 10.7326/0003-4819-137-4-200208200-00008. Ann Intern Med. 2002. PMID: 12186514

5

Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy.

Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron JJ Jr, Phillips AN, Lundgren JD. Kirk O, et al. Antivir Ther. 2002 Dec;7(4):271-81. Antivir Ther. 2002. PMID: 12553482

6

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J. Røge BT, et al. Among authors: kirk o. Antivir Ther. 2003 Apr;8(2):173-82. Antivir Ther. 2003. PMID: 12741630 Clinical Trial.

7

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group. Friis-Møller N, et al. Among authors: kirk o. AIDS. 2003 May 23;17(8):1179-93. doi: 10.1097/01.aids.0000060358.78202.c1. AIDS. 2003. PMID: 12819520

8

Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD. Gerstoft J, et al. Among authors: kirk o. AIDS. 2003 Sep 26;17(14):2045-52. doi: 10.1097/00002030-200309260-00005. AIDS. 2003. PMID: 14502007 Clinical Trial.

9

Combination antiretroviral therapy and the risk of myocardial infarction.

Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Friis-Møller N, et al. Among authors: kirk o. N Engl J Med. 2003 Nov 20;349(21):1993-2003. doi: 10.1056/NEJMoa030218. N Engl J Med. 2003. PMID: 14627784 Free article.

10

A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J. Kirk O, et al. Antivir Ther. 2003 Dec;8(6):595-602. Antivir Ther. 2003. PMID: 14760893 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

336 results

Search Page